🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

MetLife, Inc. MET SPXR3KFINANCIAL

Financial Services · Insurance - Life · United States
https://www.metlife.com
Company Profile ↓
$98.82
+31.39% 1Y
Mkt Cap$62.80B
P/E18.93
P/B2.26
Div. Yield2.43%
52W High$103.57
52W Low$66.77
Book Value$43.03
EPS (TTM)$5.22

Company Overview

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates in six segments: Group Benefits; Retirement and Income Solutions; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, paid family and medical leave, individual disability, accidental death and dismemberment, accident and health, vision, and pet insurance, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it offers fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity and funded reinsurance solutions; credit insurance products; accident & health products covering hospitalization, cancer, critical illness, income protection, and scheduled medical reimbursement plans; and protection against long-term health care services. The company was incorporated in 1999 and is based in New York, New York.

Why Investors Should Care

Dividend Income

Offers a dividend yield of 2.43%.

Recent Developments

  • Dec 2025 Revenue of $2.44B (+8.5% YoY); net profit $3.38B.
  • Trailing 12 Months Year-on-year growth — revenue +10.5%, earnings +5.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR -15.2%, profit CAGR -1.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-15.18%
1 Year:10.50%

Compounded Profit Growth

5 Years:-1.35%
1 Year:5.80%

Stock Price Performance

1 Year:+31.39%
6 Months:+28.95%
3 Months:+4.46%
1 Month:+1.61%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 87% of range
$66.77 $103.57
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)50.37 · Neutral
Price Performance
1M+1.61%
3M+4.46%
6M+28.95%
1Y+31.39%
Valuation vs Sector

P/E of 18.93 is above the sector median of 13.55 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -15.2% CAGR over 5 years.
  • Earnings shrank at -1.4% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
18.93
Industry PE
13.55
Forward P/E
9.05
PEG Ratio
0.51
Book Value
$43.03
Price to Book
2.26
P/S
0.78
EV/EBITDA
14.13
Dividend Yield
2.43%

Growth (CAGR)

Revenue 5Y
-15.18%
Profit 5Y
-1.35%
Revenue (YoY)
10.50%
Earnings (YoY)
5.80%

Profitability & Returns

ROCE
-
ROE
13.09%
ROA
0.45%
Profit Margin
4.57%
Op Margin
5.52%
Gross Margin
23.95%
EPS (Latest Qtr)
$1.09
EPS (TTM)
$5.22

Balance Sheet & Liquidity

Debt/Equity
1.80
Quick Ratio
1.71
Current Ratio
2.03
Debt
$50.31B
Total Assets
$759.37B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
16.35%
Chg in Prom Hold
0.00%
FII / Inst Holding
78.35%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
$62.80B
Total Revenue (TTM)
$79.40B
EBITDA
$6.04B
Free Cash Flow
$-20.95B
Operating Cash Flow
$15.56B
Shares Outstanding
635.48M
Gross Margin
23.95%
Payout Ratio
43.97%

Peer comparison

Peer companies in the same sector (Financial Services).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MET MetLife, Inc. SPXR3KFINANCIAL 98.82 18.93 $62.80B 2.43% - 13.09% -15.18% -1.35%
2 JPM JPMorgan Chase & Co. SPXR3KFINANCIAL 331.58 14.21 $881.40B 1.72% - 17.79% 12.50% 14.83%
3 BRK-B Berkshire Hathaway Inc. SPXFINANCIAL 542.19 13.64 $763.42B 0.00% - 12.12% 4.18% 9.44%
4 V Visa Inc. SPXR3KFINANCIAL 407.92 34.69 $695.14B 0.72% 37.15% 61.19% 14.33% 13.04%
5 MA Mastercard Incorporated SPXR3KFINANCIAL 623.60 34.34 $542.20B 0.62% 60.19% - 12.29% 19.21%
6 BRK-A Berkshire Hathaway Inc. FINANCIAL 813,595.00 13.64 $397.40B 0.00% - 12.12% 7.60% 10.02%
7 BAC Bank of America Corporation SPXR3KFINANCIAL 50.56 11.68 $353.55B 2.39% - 11.20% 3.14% 4.27%
8 HSBC HSBC Holdings plc FINANCIAL 90.68 12.95 $310.38B 3.65% - 13.10% 9.75% 12.72%
9 MS Morgan Stanley SPXR3KFINANCIAL 179.49 14.51 $281.90B 2.26% - 17.97% 3.76% 9.66%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ---------322.00M328.00M329.00M-337.00M324.00M313.00M-345.00M324.00M331.00M-515.00M514.00M516.00M550.00M525.00M511.00M-562.00M546.00M554.00M-577.00M558.00M554.00M611.00M604.00M621.00M734.00M724.00M
Operating Income --------------------------------1.40B1.66B1.44B1.42B1.39B1.65B1.63B1.60B
Net Income 834.00M2.33B321.00M542.00M-2.34B873.00M911.00M-91.00M2.32B1.25B891.00M912.00M2.07B1.38B1.74B2.18B593.00M4.40B145.00M706.00M158.00M358.00M3.41B1.58B1.63B910.00M1.16B1.58B80.00M402.00M489.00M607.00M867.00M946.00M1.34B945.00M729.00M896.00M1.19B736.00M
Diluted EPS 0.702.100.250.48-2.170.790.80-0.092.141.190.830.882.041.401.772.300.584.750.070.690.140.333.831.771.891.081.371.960.020.480.560.771.101.281.811.281.031.221.741.09

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 47.15B50.98B40.66B52.25B70.24B68.15B68.20B73.32B61.34B60.79B62.31B1.26B1.29B1.35B2.07B2.11B2.23B2.25B2.44B
Operating Income ---------------5.98B5.72B6.00B6.14B
Net Income 4.32B3.21B-2.25B2.67B6.42B1.32B3.37B6.31B5.37B850.00M4.01B5.12B5.90B5.41B6.86B5.28B1.58B4.43B3.38B
Diluted EPS 5.484.14-2.892.865.761.122.915.424.620.673.624.916.065.687.656.301.815.944.71

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Sep 2010Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --501.68B539.31B-730.91B796.23B836.78B885.30B902.34B877.93B898.76B719.89B687.54B740.46B795.15B759.71B663.07B687.58B677.46B745.17B
Total Equity 34.91B37.00B23.73B33.12B-48.62B57.52B64.45B61.55B72.21B68.10B67.53B58.68B52.74B66.14B74.56B67.48B29.88B30.02B27.45B28.40B
Cash & Equivalents 6.94B9.96B24.13B10.02B12.96B12.96B10.46B15.74B7.58B9.21B11.18B12.65B12.70B15.82B16.60B19.80B20.05B20.20B20.64B20.07B22.03B
Long Term Debt --9.67B13.22B-27.59B23.69B--------------
Total Liabilities --477.69B505.82B-681.79B738.23B771.82B822.31B829.68B809.44B831.06B661.02B634.58B674.08B720.33B691.96B632.95B657.33B649.75B716.25B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 9.90B10.70B3.80B7.99B10.27B17.16B16.13B16.38B14.05B14.77B12.28B11.74B13.79B11.64B12.35B13.04B13.72B14.60B17.09B
Investing Cash Flow -10.64B-2.67B-13.94B-18.30B-22.22B-11.93B-15.16B-15.05B-10.40B-5.85B-16.88B-5.63B-17.59B-18.57B-11.19B-2.62B-10.25B-11.49B-15.61B
Financing Cash Flow 3.94B6.19B-4.10B13.38B9.38B35.00M-8.91B2.26B-1.22B-3.50B-906.00M-2.80B4.57B10.73B-1.13B-9.95B-2.94B-3.13B163.00M
Share Buybacks 1.71B1.25B00-001.00B1.93B372.00M2.93B3.99B2.29B1.15B4.30B3.33B3.10B3.21B2.88B

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------------
Operating Margin % ---------------283.3%256.8%267.1%251.9%
Net Margin % 9.2%6.3%-5.5%5.1%9.1%1.9%4.9%8.6%8.8%1.4%6.4%407.9%457.6%399.3%330.5%250.4%70.8%197.1%138.7%
ROE % 11.7%13.5%-6.8%5.5%11.2%2.1%5.5%8.7%7.9%1.3%6.8%9.7%8.9%7.3%10.2%17.7%5.3%16.1%11.9%
ROCE % -------------------

Shareholding Pattern

Insiders
16.35%
Institutions
78.35%
Public Float
93.66%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.05% 51.79M $5.09B
2 Dodge & Cox Inc. 7.53% 48.43M $4.76B
3 Vanguard Capital Management LLC 5.51% 35.48M $3.49B
4 Vanguard Portfolio Management LLC 4.67% 30.03M $2.95B
5 State Street Corporation 3.94% 25.34M $2.49B
6 Price (T.Rowe) Associates Inc 3.31% 21.28M $2.09B
7 Geode Capital Management, LLC 2.07% 13.31M $1.31B
8 Morgan Stanley 1.95% 12.53M $1.23B
9 Pzena Investment Management LLC 1.73% 11.13M $1.09B
10 Dimensional Fund Advisors LP 1.12% 7.19M $707.06M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MET

Google News Fri, 23 Oct 2026

A Look at MetLife Inc (MET) After 4.6% Decline -- GF Value $94.84 vs Price $98.82 - GuruFocus

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNS0VnWHMtS202N2NxZFNtb0ZuUmRaQ2VDdkttUEowcEFPU2VvbWhQUFg0MDBtdmJXZVlPd1B5V3d2V0tUMi1kNWlnQjFrQXNzVDhtUGEyMVIycWRHYkFrU2xYMkVKOWMybFFoXzNjRnRPeWlUQkNPMUliOVg3M24wYXZrQW1QcV9BeTJIbG…

Google News Sat, 25 Jul 2026

MetLife (MET) Stock Looks Below Fair Value While Earnings Sit Above Fair Value - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOdE9JRGttR3lnb1pVVHk3UEkzY1lvQUotd2ZDcENDTnVkMjdpTGh3cFJKN2ZoY3hoYjRyLUtFZFZCNDRqTHhsWDNQR0N2YTg5QVdsbkZiLURnRHhyWHNvMHlvSjNMWVVleG5oMmkzODNyU0lGRjBIXzFablBRV2pIWEtNLTBQSTNHZk1nUG…

Google News hu, 22 Oct 2026

MetLife: Momentum Into Q3 Earnings, Big Technical Breakout Too (NYSE:MET) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNN1hoRHB4cWpUSU5meUpPVE5fVjIxYXM1QVBqLWlVWTNGNmRxRWx1U00xMnBGdUJrbXZab3lXa3lzVlN0REE1VEFmblVxQ0g2RmVGNVpvVEN2MkJkaVp4UlE1WTZwVFhLT0Z6Mzh0SVl2ZzF6UDBoaFN0cDJLNmtIakZYa1A1T0lPdmFURF…

Google News hu, 22 Oct 2026

Moderna stock plummets even after data confirm cancer vaccine with Merck met key endpoints in melanoma trial - The Boston Globe

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQT242QVZpcnZVQTByOFY4THF5eFlwZzNkRzNhX2toR0VtZ1BReFQ2ZEJJYnJESk1PNUlLOGh5dkFVYzlQc0VENkRZWDFDZGF1MlEtbGpxRGs0X3gtYW5BQy1DdXA3YmJ6eFBLOG1uYWFPb2JKOHVyUkM3dHhhRm1jMTlBbGNFb1Q0ajRVVF…

Google News Wed, 21 Oct 2026

MetLife (MET) Stock Forecast and Price Target 2026 $MET - MarketBeat

<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTFBOTXhTbFYtWENhYnc2anFsR3RYeXhKank0UjZpOF95M3R4djFIdHFPODhjVW9ZNWM5UFJweVJ4a1p6cTk1U0FLOXlqbWVrVkVOU2VoNEhpRkFJcG5zY2k5OFNn?oc=5" target="_blank">MetLife (MET) Stock Forecast and Pr…

Google News Wed, 21 Oct 2026

MetLife (NYSE:MET) Stock Forecast & Analyst Predictions - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE1tWWtNT0txbkNNMHhQb2RyVjdWWEhRWjEzTkRyOVdmbEZZbmVsbURjY2x0N0d5cVp3WW1wYkUwTmJndGR3OGltMFRKVzV1WVU1NktGX3lVb3ZrX0VxS3NwWUlsc0lBc0cxZi1FMW5mUWNnUEE?oc=5" target="_blank">MetLife (NYS…

MET — Frequently Asked Questions

What is the current share price of MetLife, Inc. (MET)?

As of 2026-10-23 16:27 PDT, MetLife, Inc. (MET) trades at $98.82 on NYSE. Its 52-week range is $66.77 to $103.57.

What is the market capitalisation of MET?

MetLife, Inc. (MET) has a market capitalisation of $62.80B on NYSE.

What is the P/E ratio of MET?

MET trades at a trailing price-to-earnings (P/E) ratio of 18.93. The industry average P/E is 13.55. Its price-to-book (P/B) ratio is 2.26.

Does MET pay a dividend?

MetLife, Inc. (MET) currently offers a dividend yield of 2.43%.

What is the return on equity (ROE) of MET?

MET has a return on equity (ROE) of 13.09%.

Is MET a good stock to buy?

This page provides a data-driven analysis of MetLife, Inc. (MET), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Financial Services Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space